question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
1,2026-01-22,Precision,What is the UniProt accession ID for SpCas9 (CRISPR-associated endonuclease Cas9) from Streptococcus pyogenes M1 GAS?,True,True,True,1.0,"The UniProt accession ID for SpCas9 (CRISPR-associated protein 9/Cas9) from *Streptococcus pyogenes* M1 GAS is **Q99ZW2**.

This is the widely studied Cas9 endonuclease that has become the workhorse of CRISPR genome editing technology. It comes from the *Streptococcus pyogenes* serotype M1 strain, specifically strain SF370 (also known as M1 GAS).",,4.249328136444092,84,124,True,True,1.0,"Perfect! The UniProt accession ID for SpCas9 (CRISPR-associated endonuclease Cas9) from **Streptococcus pyogenes serotype M1** is **Q99ZW2**.

This entry is specifically annotated as:
- **Protein name**: CRISPR-associated endonuclease Cas9/Csn1 (EC 3.1.-.-) 
- **Common names**: SpCas9, SpyCas9
- **Organism**: Streptococcus pyogenes serotype M1

This is the widely used Cas9 protein from the M1 GAS (Group A Streptococcus) strain that has become the standard tool for CRISPR-Cas9 genome editing applications.",,21.382292985916138,15,433,27375,53214,"mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity","[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""CRISPR-associated endonuclease Cas9 Streptococcus pyogenes M1 GAS"", ""limit"": 10}}, {""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""Cas9 Streptococcus pyogenes"", ""limit"": 10}}]",VALUABLE,Q99ZW2,Database: UniProt. Tests exact protein ID lookup for well-characterized CRISPR enzyme. Verified via search_uniprot_entity. This SpCas9 is the most commonly used Cas9 variant in genome editing applications.
2,2026-01-22,Precision,What is the ChEMBL compound ID for aspirin?,True,True,True,1.0,"The ChEMBL compound ID for aspirin is **CHEMBL25**.

Aspirin (acetylsalicylic acid) is one of the most well-known compounds in the ChEMBL database and has this relatively low numerical identifier, reflecting its importance as a widely studied drug.",,3.2846519947052,51,69,True,True,1.0,"The ChEMBL compound ID for aspirin is **CHEMBL25**.

This is the primary ChEMBL entry for aspirin (acetylsalicylic acid), which had the highest relevance score (36) in the search results. The other results shown are aspirin derivatives or combination compounds.",,15.160861015319824,9,170,26735,26489,mcp__togomcp__search_chembl_molecule,"[{""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""aspirin"", ""limit"": 5}}]",VALUABLE,CHEMBL25,Database: ChEMBL. Tests basic drug compound identification. Verified via search_chembl_molecule('aspirin'). Aspirin is one of the most well-known drugs with extensive bioactivity data.
3,2026-01-22,Completeness,How many descendant terms does the Gene Ontology term 'autophagy' (GO:0006914) have?,True,False,True,1.0,"I don't have access to the current Gene Ontology database to give you an exact count of descendant terms for GO:0006914 (autophagy). The number of descendant terms in the Gene Ontology changes over time as the ontology is continuously updated and refined.

To get the current accurate count of descendant terms for GO:0006914, I would recommend:

1. Visiting the Gene Ontology website (geneontology.org)
2. Using the AmiGO browser or QuickGO to search for GO:0006914
3. Looking at the term's page which typically shows the number of child terms and all descendants

The autophagy term is a fairly broad biological process term, so it likely has numerous descendants covering various types of autophagy (macroautophagy, microautophagy, chaperone-mediated autophagy, etc.) and their regulatory processes, but I cannot provide you with a specific number without accessing the current database.",,7.118369102478027,64,220,True,True,1.0,"Perfect! Based on the results from the Ontology Lookup Service (OLS), the Gene Ontology term **'autophagy' (GO:0006914)** has **25 descendant terms**.

The response indicates:
- **Total elements**: 25
- **Total pages**: 2 (with 20 items on page 1 and 5 items on page 2)

These descendants include various specialized types of autophagy such as:
- Major subtypes: macroautophagy, microautophagy, chaperone-mediated autophagy
- Organelle-specific: mitophagy (mitochondria), pexophagy (peroxisomes), reticulophagy (ER), nucleophagy (nucleus)
- Target-specific: lipophagy (lipid droplets), glycophagy (glycogen), ribophagy (ribosomes), aggrephagy (protein aggregates), xenophagy (pathogens)
- And other specialized forms",,20.387102842330933,12,510,17233,92448,"mcp__ols__getDescendants, mcp__ols__getDescendants","[{""name"": ""mcp__ols__getDescendants"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0006914""}}, {""name"": ""mcp__ols__getDescendants"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0006914"", ""pageNum"": 1}}]",CRITICAL,25 descendant terms,"Database: GO (Gene Ontology). Tests ability to navigate ontology hierarchies and count complete sets. Verified using OLS4:getDescendants. Includes macroautophagy, microautophagy, mitophagy, etc."
4,2026-01-22,Completeness,How many single nucleotide variants (SNVs) are recorded in ClinVar?,True,False,True,1.0,"I don't have access to real-time data about the current number of single nucleotide variants (SNVs) in ClinVar, as this database is continuously updated.

However, I can tell you that ClinVar contains **millions** of variant records, with SNVs representing the largest category of variants in the database. The last time I had specific information, ClinVar contained several million total variant submissions, with SNVs comprising the majority of these entries.

For the most current and accurate count, you would need to:
1. Visit the ClinVar website directly (ncbi.nlm.nih.gov/clinvar)
2. Check their statistics page
3. Or download their latest data release and filter for SNVs (single nucleotide variants)

The number grows regularly as new submissions are added from clinical laboratories, research groups, and expert panels worldwide.",,5.693554162979126,56,192,True,True,1.0,"Based on the query of the ClinVar RDF database, there are **3,236,823 single nucleotide variants (SNVs)** currently recorded in ClinVar.

This count represents only the ""current"" records (excluding deprecated entries) with the variation type classified as ""single nucleotide variant"". This makes SNVs by far the most common type of variant in ClinVar, which aligns with the fact that SNVs are the most prevalent form of genetic variation in the human genome.",,17.333138942718506,15,404,6825,85410,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""clinvar""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""clinvar"", ""sparql_query"": ""PREFIX cvo: <http://purl.jp/bio/10/clinvar/>\n\nSELECT (COUNT(?variant) as ?count)\nFROM <http://rdfportal.org/dataset/clinvar>\nWHERE {\n  ?variant a cvo:VariationArchiveType ;\n           cvo:variation_type \""single nucleotide variant\"" ;\n           cvo:record_status \""current\"" .\n}""}}]",CRITICAL,"3,236,823 SNVs",Database: ClinVar. Tests comprehensive variant counting. Verified via SPARQL query filtering by cvo:variation_type 'single nucleotide variant' and cvo:record_status 'current'. SNVs comprise ~90% of all ClinVar variants.
5,2026-01-22,Integration,What is the NCBI Gene ID corresponding to UniProt protein P04637?,True,True,True,1.0,"The NCBI Gene ID corresponding to UniProt protein P04637 is **7157**.

UniProt ID P04637 refers to the tumor protein p53 (TP53) in humans, which is one of the most well-studied proteins due to its critical role as a tumor suppressor. The gene encoding this protein is TP53, and its NCBI Gene ID is 7157.",,2.6090598106384277,55,92,True,True,0.5,"The NCBI Gene ID corresponding to UniProt protein **P04637** is **7157**.

This UniProt entry P04637 corresponds to the TP53 gene (tumor protein p53), which is one of the most well-studied genes in human biology, particularly in cancer research.",,13.880098104476929,8,189,476,52648,mcp__togomcp__togoid_convertId,"[{""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""P04637"", ""route"": ""uniprot,ncbigene""}}]",VALUABLE,7157 (TP53),"Databases: UniProt, NCBI Gene. Tests cross-database ID conversion. P04637 is human tumor suppressor p53. Verified via togoid_convertId from uniprot to ncbigene."
6,2026-01-22,Integration,What is the Ensembl gene ID cross-referenced to NCBI Gene ID 672 (BRCA1)?,True,True,True,1.0,"The Ensembl gene ID cross-referenced to NCBI Gene ID 672 (BRCA1) is **ENSG00000012048**.

This is the Ensembl identifier for the BRCA1 gene (Breast Cancer 1, DNA Repair Associated) in humans, which is located on chromosome 17.",,2.9767701625823975,64,78,True,True,1.0,"The Ensembl gene ID cross-referenced to NCBI Gene ID 672 (BRCA1) is **ENSG00000012048**.

This is the primary Ensembl identifier for the human BRCA1 gene, which encodes the BRCA1 DNA repair associated protein.",,16.210576057434082,8,204,501,52657,mcp__togomcp__togoid_convertId,"[{""name"": ""mcp__togomcp__togoid_convertId"", ""input"": {""ids"": ""672"", ""route"": ""ncbigene,ensembl_gene""}}]",VALUABLE,ENSG00000012048,"Databases: NCBI Gene, Ensembl. Tests cross-database linking. BRCA1 is the breast cancer susceptibility gene. Verified via insdc:dblink property in NCBI Gene SPARQL."
7,2026-01-22,Currency,How many protein structures related to CRISPR Cas9 are currently in the PDB?,True,False,False,0.2,"I don't have access to real-time data about the current contents of the Protein Data Bank (PDB), so I cannot tell you the exact number of CRISPR-Cas9 related structures currently available.

However, I can tell you that as of my training data (which has a cutoff in early 2024), there were hundreds of CRISPR-Cas9 related structures in the PDB, including:

- Cas9 nuclease structures from various species (particularly *Streptococcus pyogenes* and *Staphylococcus aureus*)
- Cas9 in complex with guide RNA
- Cas9-sgRNA-DNA ternary complexes
- Various Cas9 variants and engineered forms
- Cas9 in different conformational states

The number has been steadily growing since the first Cas9 crystal structure was published in 2014, as CRISPR technology remains a very active area of structural biology research.

To get the current, accurate count, you would need to search the PDB database directly using search terms like ""CRISPR,"" ""Cas9,"" or ""CRISPR-Cas9.""",,6.763600826263428,58,268,True,False,0.2,"Based on my search of the Protein Data Bank (PDB), there are currently **474 protein structures** related to CRISPR Cas9.

These structures include a wide variety of Cas9 variants and complexes:

- **SpCas9** (Streptococcus pyogenes Cas9) - the most commonly used variant
- **SpRY-Cas9** - an engineered variant with expanded PAM recognition
- **FnCas9** (Francisella novicida Cas9)
- **SaCas9** (Staphylococcus aureus Cas9)
- **NmeCas9** (Neisseria meningitidis Cas9)
- **xCas9** - another engineered variant

The structures capture Cas9 in various functional states:
- Alone or bound to guide RNA (gRNA/sgRNA)
- Complexed with target DNA at different stages of cleavage
- With different PAM sequences
- Bound to anti-CRISPR proteins
- Showing various conformational states (open, closed, kinked)
- With different R-loop sizes (0-18 base pairs)

This extensive collection of structures has been crucial for understanding the molecular mechanism of CRISPR-Cas9 gene editing and for engineering improved variants with altered PAM specificities and enhanced precision.",,15.930266857147217,9,447,3620,52651,mcp__togomcp__search_pdb_entity,"[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""CRISPR Cas9"", ""limit"": 100}}]",CRITICAL,461 structures (may change over time),Database: PDB. Tests access to current structural database counts. Verified via search_pdb_entity('CRISPR Cas9'). This count increases as new structures are deposited.
8,2026-01-22,Currency,How many SARS-CoV-2 related pathways are in the Reactome database?,True,False,False,0.4,"I don't have access to real-time data from the Reactome database, so I cannot tell you the exact current number of SARS-CoV-2 related pathways.

However, I can tell you that Reactome, which is a free, open-source, curated database of pathways and reactions in human biology, did add COVID-19/SARS-CoV-2 related content in response to the pandemic. They created pathways covering various aspects of SARS-CoV-2 infection, including:

- Viral entry mechanisms (ACE2 receptor binding, TMPRSS2-mediated entry)
- Viral replication and transcription
- Host immune responses
- Viral protein interactions with host proteins

The exact number of pathways would depend on:
1. When you're checking (as Reactome is regularly updated)
2. How granularly pathways are divided
3. Whether you're counting top-level pathways or including all sub-pathways

To get the current accurate number, you would need to directly query the Reactome database (www.reactome.org) or use their API to search for SARS-CoV-2 or COVID-19 related pathways.",,7.963503837585449,59,275,True,True,0.6,"Based on the search results from Reactome, I can see there are **17 SARS-CoV-2 specific pathways** in the database:

1. SARS-CoV-2 Infection
2. Replication of the SARS-CoV-2 genome
3. Transcription of SARS-CoV-2 sgRNAs
4. SARS-CoV-2 modulates autophagy
5. Early SARS-CoV-2 Infection Events
6. Late SARS-CoV-2 Infection Events
7. SARS-CoV-2 Genome Replication and Transcription
8. SARS-CoV-2-host interactions
9. SARS-CoV-2 modulates host translation machinery
10. Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC)
11. SARS-CoV-2 activates/modulates innate and adaptive immune responses
12. SARS-CoV-2 targets PDZ proteins in cell-cell junction
13. SARS-CoV-2 targets host intracellular signalling and regulatory pathways
14. Maturation of spike protein (SARS-CoV-2)
15. Attachment and Entry (SARS-CoV-2)
16. Virion Assembly and Release (SARS-CoV-2)
17. Translation of Replicase and Assembly of the Replication Transcription Complex (SARS-CoV-2)

The search also returned many SARS-CoV-1 related pathways, general SARS-CoV pathways, and various molecular complexes and reactions. The database contains comprehensive molecular-level detail about SARS-CoV-2 infection mechanisms, including viral replication, host cell interactions, immune responses, and protein maturation processes.",,21.878758192062378,9,557,19740,52652,mcp__togomcp__search_reactome_entity,"[{""name"": ""mcp__togomcp__search_reactome_entity"", ""input"": {""query"": ""SARS-CoV-2"", ""rows"": 100}}]",CRITICAL,13 pathways including R-HSA-9694516 (SARS-CoV-2 Infection),"Database: Reactome. Tests access to recently added pathway content (post-2020). Verified via SPARQL query filtering bp:displayName for 'SARS-CoV-2'. Includes infection, replication, host interaction pathways."
9,2026-01-22,Specificity,What is the MeSH descriptor ID for Erdheim-Chester disease?,True,True,True,1.0,"The MeSH descriptor ID for Erdheim-Chester Disease is **D031249**.

This is a rare form of non-Langerhans cell histiocytosis that was added to MeSH vocabulary to help with indexing and retrieval of literature related to this condition.",,3.1308460235595703,53,64,True,False,0.0,"The MeSH descriptor ID for Erdheim-Chester disease is **T459455**.

The full MeSH URI is: http://id.nlm.nih.gov/mesh/T459455",,12.659046173095703,9,151,26645,26491,mcp__togomcp__search_mesh_entity,"[{""name"": ""mcp__togomcp__search_mesh_entity"", ""input"": {""query"": ""Erdheim-Chester disease"", ""limit"": 10}}]",VALUABLE,D031249,Database: MeSH. Tests retrieval of rare disease terminology. Erdheim-Chester is a rare histiocytic disorder. Verified via search_mesh_entity('Erdheim-Chester') and SPARQL lookup.
10,2026-01-22,Specificity,What is the NANDO identifier for Parkinson's disease in the Japanese rare disease ontology?,True,False,False,0.0,"I don't have specific information about the NANDO identifier for Parkinson's disease in my training knowledge. 

NANDO (Nanbyo Disease Ontology) is the Japanese rare disease ontology, but I cannot provide the exact identifier for Parkinson's disease within that system with certainty. To find this information, you would need to consult the official NANDO database or documentation directly.

It's worth noting that whether Parkinson's disease is even classified as a rare disease in Japan may depend on the specific definition and classification criteria used, as Parkinson's disease is generally considered relatively common compared to many other neurological conditions.",,4.280595302581787,58,141,True,True,1.0,"Perfect! The NANDO identifier for Parkinson's disease in the Japanese rare disease ontology is **NANDO:1200010**.

Additional information:
- **English label**: Parkinson's disease
- **Japanese label**: パーキンソン病
- **Notification number**: 6 (officially designated intractable disease by Japanese government)
- **Alternative labels**: PD, Parkinson disease
- **MONDO mapping**: MONDO:0005180
- **External references**: KEGG Disease database and Japanese government health ministry documents

The database also contains related conditions like ""Rapid-onset dystonia-parkinsonism"" (NANDO:1200524) and ""Multiple system atrophy, Parkinsonian type"" (NANDO:1200036).",,51.669734954833984,33,1280,12397,174306,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""nando"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX dcterms: <http://purl.org/dc/terms/>\n\nSELECT DISTINCT ?disease ?label ?altLabel\nWHERE {\n  ?disease a owl:Class .\n  ?disease rdfs:label ?label .\n  FILTER(CONTAINS(LCASE(STR(?label)), \""parkinson\""))\n  OPTIONAL { ?disease obo:IAO_0000118 ?altLabel }\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""nando"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\nPREFIX nando: <http://nanbyodata.jp/ontology/nando#>\n\nSELECT DISTINCT ?disease ?label ?altLabel\nWHERE {\n  ?disease a owl:Class .\n  FILTER(STRSTARTS(STR(?disease), \""http://nanbyodata.jp/ontology/nando#\""))\n  ?disease rdfs:label ?label .\n  FILTER(CONTAINS(LCASE(STR(?label)), \""parkinson\""))\n  OPTIONAL { ?disease obo:IAO_0000118 ?altLabel }\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""nando"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?disease ?label\nWHERE {\n  ?disease rdfs:label ?label .\n  FILTER(REGEX(STR(?disease), \""nanbyodata\"", \""i\""))\n  FILTER(CONTAINS(LCASE(STR(?label)), \""parkinson\""))\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""nando""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""nando"", ""sparql_query"": ""\nPREFIX owl: <http://www.w3.org/2002/07/owl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX dct: <http://purl.org/dc/terms/>\n\nSELECT ?disease ?label ?identifier\nFROM <http://nanbyodata.jp/ontology/nando>\nWHERE {\n  ?disease a owl:Class ;\n           rdfs:label ?label ;\n           dct:identifier ?identifier .\n  ?label bif:contains \""'Parkinson*'\"" option (score ?sc) .\n}\nORDER BY DESC(?sc)\nLIMIT 20\n""}}]",CRITICAL,NANDO:1200010,"Database: NANDO. Tests specialized Japanese rare disease ontology access. Verified via SPARQL query on NANDO graph with English label filter. NANDO provides multilingual support (Japanese, English)."
11,2026-01-22,Structured Query,How many approved biochemical reactions are in the Rhea database?,True,False,True,1.0,"I don't have access to the current exact number of approved biochemical reactions in the Rhea database, as this number changes over time as the database is continuously updated and curated.

However, I can tell you that Rhea is a comprehensive resource of expert-curated biochemical reactions maintained by the Swiss Institute of Bioinformatics. As of the last information I was trained on, Rhea contained tens of thousands of biochemical reactions (likely in the range of 10,000-15,000+), but the exact current number would need to be verified from the official Rhea database website or their latest release notes.

For the most accurate and up-to-date count, I'd recommend checking the Rhea database homepage at https://www.rhea-db.org/ where they typically display current statistics about their collection.",,5.428218126296997,51,182,True,True,1.0,"Excellent! The SPARQL query confirms the exact number.

## Answer

The Rhea database contains **16,685 approved biochemical reactions** (master reactions with unspecified direction).

Additionally, the database includes:
- **34,156 directional reactions** (representing left-to-right and right-to-left directions)
- **17,078 bidirectional reactions** (reversible reactions)

All approved reactions in Rhea are chemically balanced, atom-balanced, and extensively cross-referenced to other databases including ChEBI (for chemical compounds), UniProt (for enzyme classifications), Gene Ontology, KEGG, MetaCyc, and Reactome.",,37.17247724533081,31,1025,36684,143581,"mcp__togomcp__search_rhea_entity, mcp__togomcp__get_sparql_example, mcp__togomcp__run_sparql, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": """", ""limit"": 1}}, {""name"": ""mcp__togomcp__get_sparql_example"", ""input"": {""dbname"": ""rhea""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rhea: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(?Reaction) AS ?count)\nWHERE {\n    ?Reaction a rdfs:Class ;\n        rhea:status rhea:Approved ;\n        rhea:equation ?equation .\n}""}}, {""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""rhea""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rhea: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?count)\nWHERE {\n  ?reaction rdfs:subClassOf rhea:Reaction ;\n            rhea:status rhea:Approved .\n}""}}]",CRITICAL,"16,685 approved reactions",Database: Rhea. Tests ability to filter by status and count. Verified via SPARQL with rhea:status rhea:Approved filter. Rhea serves as reference for UniProtKB enzyme annotation.
12,2026-01-22,Structured Query,How many marketed drugs (clinical development phase 4) are in ChEMBL?,True,False,True,1.0,"I don't have access to the specific current count of phase 4 drugs in ChEMBL from my training data. 

To find this information, you would need to query the ChEMBL database directly, typically by:

1. Filtering the `molecule_dictionary` table joined with `drug_mechanism` or similar tables
2. Looking for entries where `max_phase` = 4 (which indicates marketed drugs that have completed phase 4/post-marketing surveillance)

The number changes over time as ChEMBL is regularly updated with new data. The count would be in the range of several thousand compounds, but I cannot provide you with an exact number without querying the actual database.

If you need the precise current count, you would need to either:
- Query ChEMBL directly via their web interface
- Use their SQL database
- Access it through their API or Python client

I apologize that I cannot give you a more specific answer based solely on my training knowledge.",,7.054491758346558,56,220,True,True,1.0,"Based on the ChEMBL database query, there are **3,678 marketed drugs** (clinical development phase 4) in ChEMBL.

In ChEMBL's classification system, phase 4 represents marketed drugs that have been approved and are in post-marketing surveillance. This includes drugs that have successfully completed clinical trials and received regulatory approval for commercial use.",,19.665351152420044,15,379,7663,86244,"mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__get_MIE_file"", ""input"": {""dbname"": ""chembl""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT (COUNT(DISTINCT ?molecule) AS ?count)\nFROM <http://rdf.ebi.ac.uk/dataset/chembl>\nWHERE {\n  ?molecule a cco:SmallMolecule ;\n            cco:highestDevelopmentPhase 4 .\n}""}}]",CRITICAL,"3,678 marketed drugs",Database: ChEMBL. Tests structured query with phase filtering. Verified via SPARQL with cco:highestDevelopmentPhase 4 filter. Phase 4 indicates marketed/approved drugs.
